Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. - Wikidata - wikimedia - TriplyDB

Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.

Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.

http://www.wikidata.org/entity/Q39062132

about

c-Myc is Required for BRAFV600E-Induced Epigenetic Silencing by H3K27me3 in Tumorigenesis.Novel approaches in anaplastic thyroid cancer therapy Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells Effect of Hashimoto thyroiditis on low-dose radioactive-iodine remnant ablation.Response to therapy of papillary thyroid cancer of known BRAF status.Clinical guidance for radioiodine refractory differentiated thyroid cancer.Unfavorable efficacy to 131I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb.Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.

P2860

Q33836439-40DCCB12-F04F-4AFC-AF1F-28827828B5B9 Q34458018-A5B803BD-AAAF-4FD3-956C-4F23845ECBBF Q34716574-08E5AD55-E9CD-4233-890F-06049070451B Q35145064-EE94EDE5-12CF-4CF4-AFE6-473D2C216049 Q36560914-8AFFCD3A-4E14-4357-9B4B-FF973431B9FA Q36618887-461C2D5F-226A-422A-96C5-D46C2921C9B0 Q36715993-5285EE1F-78E0-4BDF-8825-55E1A32397DC Q38426754-6A982285-E464-45E8-B65C-FD89BE59E381 Q38674063-00B230FD-3246-40A4-ABAA-AFD6FF330F94 Q47863818-003EEC2C-091B-4349-AA36-185014F04360 Q49704998-2792D400-1BDA-46C6-978F-531A4FEF9443 Q52926182-B54685AF-03A3-444F-8FFD-75A8BEA64CAF

P2860

Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.

http://www.wikidata.org/entity/Q39062132

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Histone deacetylation of NIS p ...... S silencing in thyroid cancer.

@en

Histone deacetylation of NIS p ...... S silencing in thyroid cancer.

@nl

type

label

Histone deacetylation of NIS p ...... S silencing in thyroid cancer.

@en

Histone deacetylation of NIS p ...... S silencing in thyroid cancer.

@nl

prefLabel

Histone deacetylation of NIS p ...... S silencing in thyroid cancer.

@en

Histone deacetylation of NIS p ...... S silencing in thyroid cancer.

@nl

P1433

Q39062132-EAFB3412-4490-4449-A2F2-CAE09C11FF3A

P1476

Q39062132-F9DB4603-3354-4CDB-A770-DAC1C58624DD

P2093

Q39062132-82776634-5E27-4011-ADE2-BDCCFED07077

Q39062132-8A602B09-BEF9-43D9-80F9-A5C39986B41E

Q39062132-9D7F0453-8A4C-4799-9B9F-3403135AD8BB

Q39062132-A4F4D98F-803C-45CA-9154-833393C332AB

Q39062132-E7497287-8A8C-4F37-A215-8FC5FC489391

P2860

Q39062132-0B13D064-DA25-4019-A4B5-0A6ABCC18781

Q39062132-1399C9F6-8C87-4523-B7F1-77A000666712

Q39062132-365CC3A3-F00D-4F8C-AA81-820E7987D9D3

Q39062132-4BC691F4-930B-456A-B943-791342331364

Q39062132-4D74E947-0666-4693-A3B2-38815D0235CB

Q39062132-620BF9A6-86A5-48C5-A38C-0603E110DDDB

Q39062132-62C479A2-E6F8-4EC2-B0C6-C7FD7E18E17A

Q39062132-6865B6C0-7508-4481-B50E-746427DBF95F

Q39062132-6868622C-B11D-4EEB-854F-7748B5CFF966

Q39062132-6D4E726A-907D-4FD8-9CE0-F6FCCE579149

P304

Q39062132-706737F9-4A7E-4171-88A8-14541EC2E238

P31

Q39062132-80576369-05B7-42B5-B6EE-CD914B0B50ED

P356

Q39062132-CA9D9353-3CC2-41D5-8CA9-0DB491EB188E

P433

Q39062132-F6D8693F-E22A-4555-9326-2332D12514BC

P478

Q39062132-58C8C298-2BB5-47F0-8179-9CC796960DE9

P577

Q39062132-20BF209E-8469-420E-953E-4A3E7C37676E

P698

Q39062132-6FCBDD75-67F4-4DE5-BDC3-31316E91B938

P932

Q39062132-201981FE-1BD8-4C68-89C4-A125610328CF

P356

P1433

Endocrine-related cancer

P1476

Histone deacetylation of NIS p ...... S silencing in thyroid cancer.

@en

P2093

Avaniyapuram Kannan Murugan

http://www.w3.org/2001/XMLSchema#string

Dingxie Liu

http://www.w3.org/2001/XMLSchema#string

Mingzhao Xing

http://www.w3.org/2001/XMLSchema#string

Zhimin Liu

http://www.w3.org/2001/XMLSchema#string

Zongjing Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Progress in molecular-based management of differentiated thyroid cancer

The role of chromatin during transcription

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

Enhancement of sodium/iodide symporter expression in thyroid and breast cancer

Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.

Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.

Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways

DNA methylation and cancer.

Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome.

Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.

P304

161-173

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/ERC-13-0399

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24243688

http://www.w3.org/2001/XMLSchema#string

P932

3920838

http://www.w3.org/2001/XMLSchema#string